Browse
Log in / Register
Share
Published March 24, 2025
A new genetic tool developed by researchers at Stanford University is turning previously “invisible” soft cancer cells into clear targets for the immune system. The breakthrough addresses a major challenge in immunotherapy: many tumors, especially in breast, pancreatic, and brain cancers, lack the surface markers that allow immune cells to recognize and destroy them.
Soft cancer cells – those with a less rigid structure and lower expression of stress-related proteins – often evade immune surveillance. Standard immunotherapies like checkpoint inhibitors rely on the presence of specific antigens on the tumor cell surface. When those antigens are absent or masked, the immune system fails to mount an attack.
“These soft tumors are like ghosts to the immune system,” said Dr. Elena Marquez, lead author of the study published today in Nature Biotechnology. “Our tool forces them to show their ID.”
The team engineered a CRISPR-based system that activates a set of genes responsible for producing stress ligands and adhesion molecules on the surface of cancer cells. Once activated, these molecules act as “eat me” signals for natural killer cells and T cells.
In laboratory tests using patient-derived tumor organoids, the tool increased immune cell infiltration by more than 300%. The approach was also tested in mice with aggressive pancreatic tumors, where it reduced tumor volume by an average of 60% within three weeks.
Dr. James Chen, a cancer immunologist at Memorial Sloan Kettering who was not involved in the study, called the findings “promising but early.” He noted that the challenge will be delivering the gene-editing tool specifically to tumor cells without affecting healthy tissues.
“The team is already working on a nanoparticle delivery system that targets tumor-specific markers,” Marquez revealed in an exclusive interview. “If that works, we could see a clinical trial within two years.”
Immunotherapy has revolutionized cancer treatment, but it remains ineffective for many patients. The new tool could expand the pool of treatable cancers and improve outcomes for those with currently hard-to-treat tumors.
The study also highlights the role of the tumor microenvironment in immune evasion. By making soft cells “hard targets,” the tool may work alongside existing therapies to boost overall response rates.
Dr. Sarah Kim, an oncologist at the University of California, San Francisco, said: “This is a creative approach. Instead of trying to change the immune system, it changes the tumor. That could be a game-changer for patients with few options.”
The research team plans to test the tool in larger animal models and begin safety studies. If successful, the approach could be combined with checkpoint inhibitors, CAR-T therapy, or cancer vaccines.
The full study is available in Nature Biotechnology (DOI: 10.1038/s41587-025-03918-7).
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical decisions.
